Cytokinetics has developed a method for treating heart failure by administering a cardiac sarcomere activator (CSA) like omecamtiv mecarbil. The treatment involves adjusting the dose based on the subject’s plasma concentration of the CSA, ensuring effective therapy in a single step. GlobalData’s report on Cytokinetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cytokinetics, NSAID cancer drugs was a key innovation area identified from patents. Cytokinetics's grant share as of May 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Method of treating heart failure with omecamtiv mecarbil dose adjustment
A recently granted patent (Publication Number: US11986474B1) outlines a method for treating heart failure in patients by administering a cardiac sarcomere activator (CSA) called omecamtiv mecarbil. The method involves initially administering a dose of 37.5 mg of the CSA twice daily for a specified period. Subsequent dosages are determined based on the patient's plasma concentration of the CSA, with varying levels prescribed depending on the concentration levels. For instance, if the plasma concentration is less than 300 ng/mL, the second dose level is 50 mg twice daily, while concentrations above 750 ng/mL require a dosage of 25 mg twice daily. The treatment aims to achieve a target plasma concentration of 300 ng/mL to 750 ng/mL during the second period of administration.
Furthermore, the patent specifies additional details such as the timing of plasma concentration determination (2-4 weeks after initial administration), the start of the second period of treatment (approximately 4 weeks after the first dose), and the patient criteria for the treatment. Patients with chronic heart failure, New York Heart Association Class II or III heart failure, a left ventricular ejection fraction of 40% or lower, or a concentration of NT-proBNP of at least 1000 pg/mL are suitable candidates for this method. The CSA is administered orally to the patient, and the treatment regimen is designed to optimize the therapeutic benefits of omecamtiv mecarbil in managing heart failure effectively.
To know more about GlobalData’s detailed insights on Cytokinetics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
